HUMAN MONOCLONAL IGG ANTIBODIES DERIVED FROM A PATIENT ALLERGIC TO BIRCH POLLEN AS TOOLS TO STUDY THE IN-SITU LOCALIZATION OF THE MAJOR BIRCH POLLEN ALLERGEN, BET-V-1, BY IMMUNOGOLD ELECTRON-MICROSCOPY
M. Grote et al., HUMAN MONOCLONAL IGG ANTIBODIES DERIVED FROM A PATIENT ALLERGIC TO BIRCH POLLEN AS TOOLS TO STUDY THE IN-SITU LOCALIZATION OF THE MAJOR BIRCH POLLEN ALLERGEN, BET-V-1, BY IMMUNOGOLD ELECTRON-MICROSCOPY, Journal of allergy and clinical immunology, 101(1), 1998, pp. 60-66
Background: Bet v 1, the major birch pollen allergen, and related alle
rgens present in various tree pollens, fruits, and vegetables represen
t a family of important cross-reactive allergens. Although the DNA, de
duced amino-acid sequence, and structure of Bet v 1 have been determin
ed, little is known regarding its biologic functions. Objective: Human
monoclonal antibodies derived from an individual allergic to birch po
llen were used for refined ultrastructural localization of Bet v 1 in
birch pollen grains to gain information regarding the allergen distrib
ution and its possible biologic function. These data were to be supple
mented by sequence analyses. Methods: Ultrathin sections of anhydrousl
y prepared birch pollen grains were incubated with human monoclonal an
tibodies (BAB1, BAB2, and BAB4). The binding sites were visualized in
the transmission electron microscope by gold-conjugated anti-human IgG
antibodies. Results: In the cytoplasm of the birch pollen grain, huma
n monoclonal antibodies bound to ribosome-rich areas and to pollen nuc
lei. Sequence analysis of Bet v 1 and homologous allergens identified
a highly conserved p-loop motif in these proteins, which is typically
found in nucleotide-binding proteins. Conclusions: Immunolocalization
of Bet v 1 to ribosome-rich areas and the nucleus would be consistent
with a highly conserved biologic function of Bet v 1 and homologous pr
oteins as nucleotide binding proteins and explains why this group of p
lant proteins represents highly cross-reactive plant allergens against
which many type I patients are sensitized.